Arch Biopartners Inc.
ARCH.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -87.40% | -106.46% | -116.28% | 6.04% | 7.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -87.40% | -106.46% | -116.28% | 6.04% | 7.93% |
| Cost of Revenue | -94.77% | -53.41% | -22.75% | 105.87% | 80.06% |
| Gross Profit | 104.30% | -392.50% | -1,349.87% | -4,953.73% | -1,227.81% |
| SG&A Expenses | -35.22% | -36.16% | -33.13% | -15.96% | -35.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -75.62% | -44.26% | -28.49% | 50.99% | 14.54% |
| Operating Income | 68.32% | -0.77% | -52.63% | -108.34% | -19.07% |
| Income Before Tax | 61.73% | 9.24% | -38.40% | -80.81% | -17.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 61.73% | 9.24% | -38.40% | -80.81% | -17.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.73% | 9.24% | -38.40% | -80.81% | -17.46% |
| EBIT | 68.32% | -0.77% | -52.63% | -108.34% | -19.07% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 63.79% | 10.26% | -37.55% | -80.17% | -17.47% |
| Normalized Basic EPS | 63.10% | 9.52% | -37.11% | -78.77% | -17.41% |
| EPS Diluted | 63.79% | 10.26% | -37.55% | -80.17% | -17.47% |
| Normalized Diluted EPS | 63.10% | 9.52% | -37.11% | -78.77% | -17.41% |
| Average Basic Shares Outstanding | 5.34% | 2.68% | 1.46% | 0.65% | -0.29% |
| Average Diluted Shares Outstanding | 5.34% | 2.68% | 1.46% | 0.65% | -0.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |